On June 30, 2021, Shanghai, China. ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") reported that the first-in-Class drug candidate, Bi-specific recombinant fusion protein targeting human CD47and HER2 named IMM2902 received clinical trial approval from the National Medical Products Administration (NMPA) (Press release, ImmuneOnco Biopharma, JUN 30, 2021, View Source [SID1234655624]). This is the third new drug product based on CD47 of ImmuneOnco entered the clinical stage of development, and it is the cutting-edge product targeting CD47 and Her2 for immunotherapy of solid tumors, another major milestone for the company.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to learn that our clinical trial application for IMM2902 has been approved by the NMPA. IMM2902 is a bi-specific molecule for binding CD47 and HER2, developed based on our MAB-TRAP technology platform. The high affinity activity of HER2 enables the molecule to bind preferentially to tumor cells. at the same time, it retains the advantage feature of avoiding binding to human red blood cells, the "Antigenic sink", which greatly strengthens the tumor-specific synergistic effect of double targets. "We believe that IMM2902 has promising clinical value." Dr. Tian Wenzhi, founder of the company, is confident in IMM2902 clinical development.